A DIFFICULT DIAGNOSIS AND CHALLENGING MANAGEMENT OF AN AGGRESSIVE CASE OF AQUAPORIN 4 NEGATIVE NMOSD

Authors

  • Amna Khan Shifa International Hospital Islamabad
  • Warda Zahoor Shifa International Hospital Islamabad
  • Taskeen Zehra Shifa International Hospital Islamabad
  • Zafar Ullah Shifa International Hospital Islamabad https://orcid.org/0009-0009-6174-1113
  • Nabeel Muzaffar Syed Shifa International Hospital Islamabad https://orcid.org/0000-0001-8901-5601

DOI:

https://doi.org/10.55519/JAMC-03-11914

Keywords:

Neuromyelitis Optica Spectrum Disorder, Rituximab, Demyelinating Disease

Abstract

Neuromyelitis optica spectrum disorders can be challenging to diagnose and manage. There is considerable potential long term morbidity but this can be avoided by appropriate treatment. Here we present one such case that is interesting as well as instructive.

References

Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med (Lond). 2019 Mar;19(2):169-176.

doi:10.7861/clinmedicine.19-2-169

Lana-Peixoto MA, Talim N. "Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes". Biomedicines 2019;7(2):42.

Levin MC. Neuromyelitis optica spectrum disorder. Kenilworth (NJ): Merck Manuals. 2020.

Albutt T. On the opthalmoscopic signs of spinal disease. Lancet 1870;1:76–8.

Devic E. Myélite subaiguë compliquée de névrite optique. Bull Med 1894;8:1033–4.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106–12.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International Panel for NMO Diagnosis 2015. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–89.

Additional Files

Published

2023-07-11